Clinical Trial Update: Erythropoietin (EPO) and Granulocyte-Colony Stimulating Factor (G-CSF) for Low-Risk Myelodysplastic Syndromes (MDS) [Phase 2, Phase 3]

View source ↗

Summary

This clinical trial update reports on Phase 2/Phase 3 testing of erythropoietin (epoetin alfa) and granulocyte-colony stimulating factor (filgrastim) for patien…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• Erythropoietin (erythropoietin)
• Filgrastim (G-CSF) (filgrastim)

Snippet

Sponsor: St. Bartholomew's Hospital | Conditions: Myelodysplastic Syndromes | Phase 2, Phase 3 | Status: UNKNOWN